Radiomic predicts early response to CDK4/6 inhibitors in hormone receptor positive metastatic breast cancer

The combination of Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) and endocrine therapy (ET) is the standard of care for hormone receptor-positive (HR + ), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC). Currently, there are no robust biomarkers that can p...

Descripción completa

Detalles Bibliográficos
Autores principales: Khorrami, Mohammadhadi, Viswanathan, Vidya Sakar, Reddy, Priyanka, Braman, Nathaniel, Kunte, Siddharth, Gupta, Amit, Abraham, Jame, Montero, Alberto J., Madabhushi, Anant
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10421862/
https://www.ncbi.nlm.nih.gov/pubmed/37567880
http://dx.doi.org/10.1038/s41523-023-00574-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10421862/
https://www.ncbi.nlm.nih.gov/pubmed/37567880
http://dx.doi.org/10.1038/s41523-023-00574-7

Ejemplares similares